Maryland’s prescription drug affordability review board is looking at whether to set health plan payment limits for the blockbuster diabetes drug Ozempic, along with other products from companies that have sued the Biden administration over Medicare price negotiations.
Maryland’s PDAB, ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.